of eliminating racial/ethnic disparities in health care.
Year: 2005
Type: preprint
Abstract: Recent Food and Drug Administration (FDA) approval of the first drug with a race-specific indication has fueled the controversy over the meaning of race and ethnicity and raised questions over whether this move should be seen as an advance or a setback in the struggle to address disparities in health status associated with race. The drug, BiDil, combines two generics long recognized as benefiting patients with heart failure, irre- spective of race or ethnicity. The push to bring these drugs to market as a race-specific treatment was motivated by the peculiarities of U.S. patent law and a willingness to exploit race to gain commercial and regulatory advantage.
Source: SSRN Electronic Journal
Authors: Pamela Sankar, Jonathan Kahn
Language: English
Topic: Race, Genetics, and Society
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2184276289